How to Overcome Scientific Standstill for Very Rare Diseases: Clinical Trials or Clinical Registries?

• References

• 1 Al-Mansour M, Connors JM, Gascoyne RD et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 793-799
• 2 Biasoli I, Stamatoullas A, Meignin V et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116: 631-639
• 3 Fanale MA, Lai C, McLaughlin P et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (NLPHL) Patients treated with R-CHOP. Blood (ASH Annual Meeting Abstracts) 2010; 116 Abstract 2812
• 4 Griese M, Haug M, Hartl D et al. for the National EAA Study Group. Hypersensitivity pneumonitis: lessons for diagnosis and treatment of a rare entity in children. Orphanet J Rare Dis 2013; 8: 121
• 5 Hartmann S, Agostinelli C, Diener J et al. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer 2012; 12: 586
• 6 Kölch M, Lippert H-D, Fegert JM. Die Auswirkungen der 12. und der 14. Novelle zum AMG auf die Forschung mit Arzneimitteln für Kinder. Z Kinder Jugendpsychiatr Psychother 2006; 34: 117-126
• 7 Kurch L, Mauz-Körholz C, Bertling S et al. The EuroNet paediatric Hodgkin network – modern imaging data management for real time central review in multicentre trials. Klin Padiatr 2013; 225: 357-361
• 8 Mauz-Körholz C, Lange T, Hasenclever D et al. Pediatric nodular lymphocyte-predominant Hodgkin Lymphoma: Treatment recommendations of the GPOH-HD study group. Klin Padiatr 2015; 227 312–319
• 9 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Hodgkin Lymphom – S3 Leitlinie Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten Version 1.0; Februar 2013 Registrierungsnummer 018/0290L http://www.krebsgesellschaft.de/dwonload/s3_hodgkin-ol-langversion.pdf
• 10 Nogová L, Reineke T, Brillant C et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434-439
• 11 Reinhardt K, Weiss S, Rosenbauer J et al. Multiple sclerosis in children and adolescents: incidence and clinical picture – new insights from the nationwide German surveillance (2009-2011). Eur J Neurol 2014; 21: 654-659
• 12 Stark D, Lewis I. Improving outcomes for teenagers and young adults (TYA) with cancer. Klin Padiatr 2013; 225: 331-334
• 13 Schneider DT. Registries, diagnostic studies, and therapeutic interventional trials: Generating evidence in a broad perspective. Klin Padiatr 2013; 225: 293-295
• 14 Thiele KP, Rheineberger P. « Unmöglich » gibt es nicht. Dtsch Ärzteblatt 2003; 100: A1044-A1046
• 15 Tibussek 1 D, Distelmaier F, von Kries R et al. Pseudotumor cerebri in childhood and adolescence – results of a Germany-wide ESPED-survey. Klin Padiatr 2013; 225: 81-85
• 16 Zwölftes Gesetz zur Änderung des Arzneimittelgesetzes. Bundesgesetzblatt 2004; 41: 2031-2053